Anagrelide: 20 years later

References

• Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin. Thromb. Hemost.23(5), 425–431 (1997).
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet–von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin. Thromb. Hemost.32(6), 589–604 (2006).
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med.102(4), 466–471 (1985).
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology, 43(6), 1107–1110 (1993).
   PubMed Web of Science ®Google Scholar
• Jabaily J, Iland HJ, Laszlo J et al. Neurologic manifestations of essential thrombocythemia. Ann. Intern. Med.99(4), 513–518 (1983).
   PubMed Web of Science ®Google Scholar
• Michiels JJ, van Genderen PJ, Jansen PH, Koudstaal PJ. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk. Lymphoma22(Suppl. 1), 65–70 (1996).
   PubMed Web of Science ®Google Scholar
• Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res.15(3–4), 373–388 (1979).
   PubMed Web of Science ®Google Scholar
• Baryla UM, Fleming JS, Stanton HC. The anesthetized ferret, an in vivo model for evaluating inotropic activity: effects of milrinone and anagrelide. J. Pharmacol. Methods20(4), 299–306 (1988).
   Google Scholar
• Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br. J. Pharmacol.146(3), 324–332 (2005).
   PubMed Web of Science ®Google Scholar
• Gaver RC, Deeb G, Pittman KA, Smyth RD. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin. Pharmacol. Ther.29(3), 381–386 (1981).
   PubMed Web of Science ®Google Scholar
• Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am. J. Health Syst. Pharm.55(19), 1979–1986 (1998).
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs66(1), 111–131 (2006).
   PubMed Web of Science ®Google Scholar
• Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood99(5), 1602–1609 (2002).
   PubMed Web of Science ®Google Scholar
• Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood79(8), 1931–1937 (1992).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin. Thromb. Hemost.23(4), 379–383 (1997).
   PubMed Web of Science ®Google Scholar
• Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia20(6), 1117–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Lane WJ, Hattori K, Dias S et al. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp. Hematol.29(12), 1417–1424 (2001).
   PubMed Web of Science ®Google Scholar
• Erusalimsky JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp. Hematol.30(7), 625–626; author reply: 626–627 (2002).
   Google Scholar
• McCarty JM, Melone PD, Simanis JP, Kanamori D, Dessypris EN, Warshamana-Greene GS. A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions. Exp. Hematol.34(1), 87–96 (2006).
   Google Scholar
• Birgegard G, Bjorkholm M, Kutti J et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica89(5), 520–527 (2004).
   PubMed Web of Science ®Google Scholar
• Solberg LA Jr, Tefferi A, Oles KJ et al. The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol.99(1), 174–180 (1997).
   PubMed Web of Science ®Google Scholar
• Tomer A, Harker LA. Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients. Stem Cells14(Suppl. 1), 18–30 (1996).
   PubMedGoogle Scholar
• Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol. Histopathol.20(4), 1071–1076 (2005).
   PubMed Web of Science ®Google Scholar
• Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol.106(3), 682–688 (1999).
   PubMed Web of Science ®Google Scholar
• Cacciola RR, Francesco ED, Giustolisi R, Cacciola E. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Br. J. Haematol.126(6), 885–886 (2004).
   PubMedGoogle Scholar
• Cacciola RR, Cipolla A, Di Francesco E, Giustolisi R, Cacciola E. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. Am. J. Hematol.80(1), 81–83 (2005).
   PubMed Web of Science ®Google Scholar
• Lev PR, Salim JP, Kornblihtt LI et al. PDGF-A, PDGF-B, TGFβ, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. Am. J. Hematol.78(2), 155–157 (2005).
   Google Scholar
• Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica88(10), 1130–1138 (2003).
   PubMed Web of Science ®Google Scholar
• Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med.318(20), 1292–1294 (1988).
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica77(4), 315–317 (1992).
   PubMed Web of Science ®Google Scholar
• Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica77(1), 40–43 (1992).
   PubMed Web of Science ®Google Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur. J. Haematol.61(2), 71–76 (1998).
   PubMed Web of Science ®Google Scholar
• Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol. Dis.24(1), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Mills AK, Taylor KM, Wright SJ et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust. NZ J. Med.29(1), 29–35 (1999).
   PubMedGoogle Scholar
• Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin. Appl. Thromb. Hemost.6(3), 157–161 (2000).
   PubMed Web of Science ®Google Scholar
• Knutsen H, Hysing J. [Anagrelide in primary thrombocythemia]. Tidsskr. Nor. Laegeforen.121(12), 1478–1482 (2001).
   Google Scholar
• Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood97(4), 863–866 (2001).
   PubMed Web of Science ®Google Scholar
• Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience]. Medicina (B. Aires)62(3), 231–236 (2002).
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Redi R, Bernasconi S et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica89(11), 1306–1313 (2004).
   PubMed Web of Science ®Google Scholar
• Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer101(10), 2239–2246 (2004).
   PubMed Web of Science ®Google Scholar
• Penninga E, Jensen BA, Hansen PB et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin. Lab. Haematol.26(5), 335–340 (2004).
   PubMedGoogle Scholar
• Silver RT. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia19(1), 39–43 (2005).
   PubMed Web of Science ®Google Scholar
• Penka M, Schwarz J, Pavlik T et al. [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006]. Vnitr Lek.53(6), 653–661 (2007).
   Google Scholar
• Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med.92(1), 69–76 (1992).
   PubMed Web of Science ®Google Scholar
• Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hematol.34(1), 51–54 (1997).
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk. Res.29(5), 481–491 (2005).
   PubMed Web of Science ®Google Scholar
• Lackner H, Urban C, Benesch M et al. Long-term use of anagrelide in the treatment of children with essential thrombocythemia. Eur. J. Haematol.77(4), 358–359 (2006).
   Google Scholar
• Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med.353(1), 33–45 (2005).
   PubMed Web of Science ®Google Scholar
• Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin. Hematol.34(1), 29–39 (1997).
   PubMed Web of Science ®Google Scholar
• Cassinat B, Laguillier C, Gardin C et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia22(2), 452–453 (2008).
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood109(6), 2310–2313 (2007).
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Evangelista V et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood96(13), 4261–4266 (2000).
   PubMed Web of Science ®Google Scholar
• Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood108(1), 184–191 (2006).
   PubMed Web of Science ®Google Scholar
• Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood111(3), 1117–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Gambero S, Canalli AA, Traina F et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur. J. Haematol.78(2), 144–151 (2007).
   PubMed Web of Science ®Google Scholar
• Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica93(4), 605–609 (2008).
   PubMed Web of Science ®Google Scholar
• Petrides PE. Anagrelide: what was new in 2004 and 2005? Semin. Thromb. Hemost.32(4 Pt 2), 399–408 (2006).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet366(9501), 1945–1953 (2005).
   PubMed Web of Science ®Google Scholar
• Raghavan M, Mazer MA, Brink DJ. Severe hypersensitivity pneumonitis associated with anagrelide. Ann. Pharmacother.37(9), 1228–1231 (2003).
   Google Scholar
• Rodwell GE, Troxell ML, Lafayette RA. Renal tubular injury associated with anagrelide use. Nephrol. Dial. Transplant.20(5), 988–990 (2005).
   Google Scholar
• Wong RS, Lam LW, Cheng G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Ann. Hematol. DOI: 10.1007/s00277-008-0451-6 (2008) (Epub ahead of print).
   Google Scholar
• Hultdin M, Sundstrom G, Wahlin A et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med. Oncol.24(1), 63–70 (2007).
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood100(7), 2292–2302 (2002).
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood111(3), 981–986 (2008).
   PubMed Web of Science ®Google Scholar
• Stenberg PE, Levin J. Mechanisms of platelet production. Blood Cells15(1), 23–47 (1989).
   PubMedGoogle Scholar
• Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest.115(12), 3348–3354 (2005).
   PubMed Web of Science ®Google Scholar
• Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: the megakaryocyte example. J. Cell. Physiol.190(1), 7–20 (2002).
   PubMed Web of Science ®Google Scholar
• Odell TT Jr, Jackson CW, Friday TJ. Megakaryocytopoiesis in rats with special reference to polyploidy. Blood35(6), 775–782 (1970).
   PubMed Web of Science ®Google Scholar
• Patel SR, Richardson JL, Schulze H et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood106(13), 4076–4085 (2005).
   PubMed Web of Science ®Google Scholar
• Richardson JL, Shivdasani RA, Boers C, Hartwig JH, Italiano JE Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood106(13), 4066–4075 (2005).
   PubMed Web of Science ®Google Scholar
• Kaushansky K. The molecular mechanisms that control thrombopoiesis. J. Clin. Invest.115(12), 3339–3347 (2005).
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood85(10), 2720–2730 (1995).
   PubMed Web of Science ®Google Scholar
• Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb. Haemost.86(6), 1421–1424 (2001).
   PubMedGoogle Scholar
• Kaser A, Brandacher G, Steurer W et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood98(9), 2720–2725 (2001).
   PubMed Web of Science ®Google Scholar
• Syed NN, Usman M, Khurshid M. Thrombocytosis: age dependent aetiology and analysis of platelet indices for differential diagnosis. Indian J. Pathol. Microbiol.50(3), 628–633 (2007).
   Google Scholar
• Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets17(5), 328–331 (2006).
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J. Intern. Med.245(3), 295–300 (1999).
   PubMed Web of Science ®Google Scholar
• Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J. Intern. Med.229(6), 493–495 (1991).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev.15(3), 121–131 (2001).
   PubMed Web of Science ®Google Scholar
• Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am. J. Hematol.20(4), 365–372 (1985).
   PubMed Web of Science ®Google Scholar
• Bellucci S, Janvier M, Tobelem G et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer58(11), 2440–2447 (1986).
   PubMed Web of Science ®Google Scholar
• Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann. Hematol.63(2), 101–106 (1991).
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Hochhaus A, Kronawitter U et al. Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br. J. Haematol.100(1), 15–23 (1998).
   PubMed Web of Science ®Google Scholar
• Besses C, Cervantes F, Pereira A et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia13(2), 150–154 (1999).
   PubMed Web of Science ®Google Scholar
• Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit. Rev. Oncol. Hematol.20(3), 203–222 (1995).
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br. J. Haematol.128(3), 275–290 (2005).
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol.8(3), 556–562 (1990).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin. Proc.76(1), 22–28 (2001).
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. Extreme thrombocytosis: what are the etiologies? Clin. Appl. Thromb. Hemost.12(1), 85–87 (2006).
   Web of Science ®Google Scholar
• Buss DH, Cashell AW, O’Connor ML, Richards F 2nd, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am. J. Med.96(3), 247–253 (1994).
   PubMed Web of Science ®Google Scholar
• Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost.32(3), 171–173 (2006).
   PubMed Web of Science ®Google Scholar
• Green AR, Vassiliou GS, Curtin N, Campbell PJ. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol. J.5(Suppl. 3), S126–S132 (2004).
   Google Scholar
• Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann. Intern. Med.139(6), 470–475 (2003).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Green AR. The myeloproliferative disorders. N. Engl. J. Med.355(23), 2452–2466 (2006).
   PubMed Web of Science ®Google Scholar
• Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer67(10), 2658–2663 (1991).
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am. J. Med.117(10), 755–761 (2004).
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood108(12), 3913–3915 (2006).
   PubMed Web of Science ®Google Scholar
• Wilkins BS, Erber WN, Bareford D et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood111(1), 60–70 (2008).
   PubMed Web of Science ®Google Scholar
• Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood112(2), 231–239 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitt-Graeff AH, Teo SS, Olschewski M et al.JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica93(1), 34–40 (2008).
   PubMed Web of Science ®Google Scholar
• Spivak JL. Phenotype and genotype in the myeloproliferative disorders. Eur. J. Haematol.79(Suppl. 68), 9–12 (2007).
   Google Scholar
• Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica91(3), 413–414 (2006).
   PubMed Web of Science ®Google Scholar
• Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. Development of erythrocytosis in the course of essential thrombocythemia. Ann. Hematol.78(5), 219–222 (1999).
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med.350(2), 114–124 (2004).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood109(12), 5104–5111 (2007).
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica89(2), 215–232 (2004).
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med.332(17), 1132–1136 (1995).
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br. J. Haematol.103(3), 772–777 (1998).
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood.110(3), 840–846 (2007).
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM et al.JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br. J. Haematol.131(2), 208–213 (2005).
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica93(3), 372–380 (2008).
   PubMedGoogle Scholar
• Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol.85(3), 124–127 (1991).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev.19(5), 243–252 (2005).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann. Hematol.78(9), 389–392 (1999).
   PubMed Web of Science ®Google Scholar
• Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferative disorders. Hematology200–224 (2003).
   Google Scholar
• Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc.73(10), 961–963 (1998).
   PubMed Web of Science ®Google Scholar
• De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin. Exp. Dermatol.29(6), 605–607 (2004).
   Google Scholar
• Adams M, Warr JR. The mutagenic activity of hydroxyurea in Chlamydomonas reinhardi. Mutat. Res.41(2–3), 217–224 (1976).
   Google Scholar
• Ziegler-Skylakakis K, Schwarz LR, Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat. Res.152(2–3), 225–231 (1985).
   Google Scholar
• de Lima PD, Cardoso PC, Khayat AS, Bahia Mde O, Burbano RR. Evaluation of the mutagenic activity of hydroxyurea on the G1–S–G2 phases of the cell cycle: an in vitro study. Genet. Mol. Res.2(3), 328–333 (2003).
   Google Scholar
• Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol.74(1), 26–31 (2003).
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood90(9), 3370–3377 (1997).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost.32(4 Pt 2), 417–421 (2006).
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Griesshammer M, Hehlmann R. Interferon-α in the treatment of essential thrombocythemia. Leuk. Lymphoma22(Suppl. 1), 135–142 (1996).
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Bergmann L, Pearson T. Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin. Haematol.11(4), 859–874 (1998).
   PubMedGoogle Scholar
• Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α2a. Blood108(6), 2037–2040 (2006).
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Berger U, Hehlmann R. Interferon α in the treatment of polycythemia vera. Ann. Hematol.79(3), 103–109 (2000).
   PubMed Web of Science ®Google Scholar
• Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch. Intern. Med.149(9), 1959–1961 (1989).
   PubMed Web of Science ®Google Scholar
• Ogston D. Current status of antifibrinolytic drugs. Blood Rev.3(1), 1–4 (1989).
   Google Scholar
• Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica93(9), 1412–1414 (2008).
   PubMed Web of Science ®Google Scholar